Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 84 of 5804
-
New drug cocktail shows promise in liver cancer fight
Disease control OngoingA global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients with locoregional hepatocellular carcinoma
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Brain cancer breakthrough? new combo aims to shrink tumors in Hard-to-Treat glioblastoma
Disease control OngoingThis phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more …
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for lung cancer: targeted drug telisotuzumab vedotin faces off against chemo
Disease control Recruiting nowCancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine if telisotuzumab vedotin…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New Immune-Boosting drug aims to outperform standard therapy in myeloma
Disease control OngoingThe purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug cocktail shows promise in lung cancer battle
Disease control CompletedThe primary hypothesis is that pembrolizumab/vibostolimab (MK-7684A) in combination with chemotherapy is superior to pembrolizumab in combination with chemotherapy with respect to overall survival (OS) in participants with programmed cell death-ligand 1 (PD-L1) tumor proportion s…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New daily shot could help kids with hemophilia avoid bleeds
Disease control OngoingThis study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use. Participants will have to inject the study medicine every d…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Nasal spray vaccine aims to shield infants from RSV
⭐️ VACCINE ⭐️ CompletedThe purpose of this study is to evaluate the infectivity, safety, and immunogenicity of a single dose of a recombinant, live-attenuated respiratory syncytial virus (RSV) vaccine, LID/ΔM2-2/1030s, in RSV-seronegative infants and children 6 to 24 months of age.
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 22, 2026 00:00 UTC
-
Kidney cancer combo aims to stop recurrence after surgery
Disease control OngoingThe purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy. The primary st…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New targeted combo shows promise for tough stomach cancer
Disease control TerminatedThe main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) and nivolumab. The main objective Part 2 is to compare efficacy of bemarituzumab plus chemotherapy (mFOLFOX6 or capecitabine combi…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a lighter immunotherapy schedule keep advanced cancers in check?
Disease control OngoingImmunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers. However, the optimal duration of immunotherapies is currently unknown. Our hypothesis is…
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New targeted combo shows promise for tough stomach cancer
Disease control CompletedThe main objective of this study is to compare efficacy of bemarituzumab combined with oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (mFOLFOX6) to placebo plus mFOLFOX6 as assessed by overall survival (OS) in participants with FGFR2b ≥10% 2+/3+ tumor cell staining (FGFR2b ≥1…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New pill combo aims to stall advanced breast cancer
Disease control OngoingThis study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer. A placebo is a pill that looks the same as tucatinib but has no medicine in it. This study will also test what side effects h…
Phase: PHASE3 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a simple kit cut newborn deaths by 25%? a major trial in pakistan aims to find out
Prevention CompletedNeonatal deaths account for almost half of all deaths in children under 5 years of age. Pakistan has the world's highest neonatal mortality rate (NMR), and many of these deaths are preventable. In this study, the investigators propose the use of an evidence-based, integrated newb…
Phase: NA • Sponsor: The Hospital for Sick Children • Aim: Prevention
Last updated Jul 24, 2026 00:00 UTC
-
One shot to stop cancer: HPV vaccine study could change global prevention
Prevention OngoingThis phase IV trial tests whether a single dose of the human papillomavirus (HPV) vaccine works in preventing cervical cancer in young women in Costa Rica. Human papilloma viruses, called HPV, are a group of viruses that very frequently cause infection in both men and women, main…
Phase: PHASE4 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Jul 02, 2026 00:00 UTC
-
Bladder cancer patients may avoid surgery with new drug
Disease control OngoingThis Phase 3, multinational, single-arm study was designed to evaluate the efficacy and safety of UGN-102 as primary chemoablative therapy in patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
Phase: PHASE3 • Sponsor: UroGen Pharma Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Simple blood test aims to catch liver cancer before It's too late
Diagnosis Recruiting nowThe objective of this study is the acquisition of whole blood samples and serum samples from participants with untreated Hepatocellular Carcinoma (HCC) and subjects undergoing Hepatocellular Carcinoma (HCC) surveillance. These samples will be used for research purposes to develop…
Sponsor: Helio Genomics • Aim: Diagnosis
Last updated Jul 12, 2026 00:00 UTC
-
Experimental virus and immunotherapy combo takes on deadly brain tumors
Disease control Recruiting nowThis Phase I (Cohort I and Cohort II) and Phase II trial is designed to confirm the safety and tolerability of Pembrolizumab when given in conjunction with M032, an Oncolytic Herpes Simplex Virus (oHSV) that expresses IL-12 and perform the Phase II portion using a Recommended Pha…
Phase: PHASE1, PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental gene therapy aims to halt devastating brain disease in infants
Disease control TerminatedPBKR03 is a gene therapy for Krabbe Disease (Globoid cell leukodystrophy) intended to deliver a functional copy of the GALC gene to the brain and peripheral tissues. This study will evaluate the safety, tolerability and efficacy of this treatment by first evaluating two different…
Phase: PHASE1, PHASE2 • Sponsor: Gemma Biotherapeutics • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New stent graft aims to fix Hard-to-Reach aneurysms while saving key arteries
Disease control CompletedA prospective, multi-center, objective performance criteria clinical trial to evaluate the safety and efficacy of WeFlow-JAAA stent graft system manufactured by Hangzhou Endonom Medtech Co., Ltd. for the complex abdominal aortic aneurysm.
Phase: NA • Sponsor: Hangzhou Endonom Medtech Co., Ltd. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for early lung cancer: pill may keep disease from returning
Disease control OngoingThis is a global study to assess the effects of osimertinib in participants with EGFRm stage IA2-IA3 non-small cell lung cancer following complete tumour resection.
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC